Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma 25Central Nervous System Neoplasms 18Astrocytoma 15Gliosarcoma 14Glioblastoma 14Ovarian Neoplasms 12Oligodendroglioma 10Neuroectodermal Tumors, Primitive, Peripheral 10Brain Neoplasms 10Osteosarcoma 9Neuroblastoma 9Testicular Neoplasms 8Glioma 8Dendritic Cell Sarcoma, Interdigitating 8Medulloblastoma 7Breast Neoplasms 7Choroid Plexus Neoplasms 6Carcinosarcoma 6Burkitt Lymphoma 6Wilms Tumor 5Testicular Germ Cell Tumor 5Stomach Neoplasms 5Rhabdoid Tumor 5Optic Nerve Glioma 5Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Kidney Neoplasms 5Head and Neck Neoplasms 5Retinoblastoma 4

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Adenocarcinoma × Carboplatin × Sarcoma × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡